
Find out why Option Care Health's -34.8% return over the last year is lagging behind its peers.
A Discounted Cash Flow, or DCF, model projects a company’s future cash flows and then discounts them back to today’s dollars, aiming to estimate what the entire business might be worth right now.
For Option Care Health, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month Free Cash Flow is about $208.3 million. Analysts provide forecasts out to 2028, with Simply Wall St extrapolating beyond that, including a projected Free Cash Flow of $179.5 million in 2035. These projections are then discounted using the model’s required return assumptions, expressed in the ten year FCF schedule, to calculate a present value for each year.
Bringing all those discounted cash flows together, the DCF model arrives at an estimated intrinsic value of about $25.08 per share. Compared with the recent share price of $20.93, this suggests the stock trades at around a 16.5% discount to that DCF estimate, indicating that the shares may be undervalued on this measure.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Option Care Health is undervalued by 16.5%. Track this in your watchlist or portfolio, or discover 48 more high quality undervalued stocks.
For profitable companies, the P/E ratio is a useful way to relate what you pay for the stock to the earnings the business is currently generating. It gives you a quick sense of how many dollars investors are willing to pay today for each dollar of earnings.
What counts as a "normal" or "fair" P/E depends on how the market views a company’s growth prospects and risk. Higher expected growth and lower perceived risk often justify a higher multiple, while slower growth or higher risk usually mean a lower one.
Option Care Health currently trades on a P/E of 15.9x. That sits below the Healthcare industry average of 24.6x and also below the peer group average of 82.6x. Simply Wall St’s Fair Ratio for Option Care Health is 23.0x. This Fair Ratio is a proprietary estimate of what the P/E might be given the company’s earnings growth profile, profit margins, industry, market capitalization and key risks.
Compared with a simple industry or peer comparison, the Fair Ratio aims to be more tailored to the company’s own characteristics, rather than assuming that all healthcare stocks deserve the same multiple.
Because Option Care Health’s current P/E of 15.9x is below the Fair Ratio of 23.0x, the stock screens as undervalued on this measure.
Result: UNDERVALUED
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.
Earlier it was mentioned that there is an even better way to understand valuation, so meet Narratives, which let you connect your view of Option Care Health’s business to specific forecasts for revenue, earnings and margins, then translate that into a Fair Value you can compare with today’s share price.
On Simply Wall St’s Community page, Narratives are presented as easy to use story plus forecast combinations where you can see, for example, one investor aligning with a more optimistic Fair Value around US$38.52 and another aligning with a more cautious Fair Value around US$22.00. Both are built from different assumptions about future growth, margins and the P/E the stock might trade on.
Because Narratives sit on top of live data, they are refreshed whenever new information such as earnings releases or news is added. This helps you keep your Option Care Health story and Fair Value up to date and decide whether the current price looks high, low or roughly in line with the scenario you find most reasonable.
Do you think there's more to the story for Option Care Health? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com